No Data
No Data
Press Release: Ocular Therapeutix(TM) Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix(TM) Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) BEDFORD, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL) ("Ocular"), a
Ocular Therapeutix (OCUL) Gets a Buy From Piper Sandler
Investors Await Earnings Reports, Tech Stocks Take Hit as US Futures Fall Sharply Pre-Bell
US stock futures are trending sharply lower in Wednesday's premarket session as investors look toward more corporate earnings reports.Semiconductor stocks were hit particularly hard on media reports
Institutional Investors Have a Lot Riding on Ocular Therapeutix, Inc. (NASDAQ:OCUL) With 64% Ownership
Key Insights Institutions' substantial holdings in Ocular Therapeutix implies that they have significant influence over the company's share price 52% of the business is held by the top 9
The One-year Returns Have Been Notable for Ocular Therapeutix (NASDAQ:OCUL) Shareholders Despite Underlying Losses Increasing
Piper Sandler Sticks to Their Buy Rating for Ocular Therapeutix (OCUL)
No Data